India Plasma Fractionation Market Size
| Study Period | 2019 - 2030 |
| Base Year For Estimation | 2024 |
| Forecast Data Period | 2025 - 2030 |
| Market Size (2025) | USD 1.77 Billion |
| Market Size (2030) | USD 2.41 Billion |
| CAGR (2025 - 2030) | 6.39% |
| Market Concentration | Low |
Major Players*Disclaimer: Major Players sorted in no particular order |
India Plasma Fractionation Market Analysis
The India Plasma Fractionation Market size is estimated at USD 1.77 billion in 2025, and is expected to reach USD 2.41 billion by 2030, at a CAGR of 6.39% during the forecast period (2025-2030).
Factors such as the growing use of immunoglobulins in various therapeutic areas, the rising geriatric population, and the rising prevalence of rare diseases are expected to drive market growth in India. For instance, according to the report published by Observer Research Foundation in July 2022, a higher prevalence of β-thalassemia was observed in pockets of Gujarat, Punjab, West Bengal, Odisha, and Andhra Pradesh than in the rest of the country. Mostly, patients with β-thalassemia major are advised to take leucoreduced packed red blood cells with a minimum hemoglobin content of 40 grams. Thus, due to the utilization of plasma cells for treating rare diseases like thalassemia, the demand in the market is expected to witness significant growth during the forecast period. Moreover, investments by key companies in India to develop plasma products are expected to create a demand for them. For instance, in September 2022, Reliance Life Sciences invested up to INR 2,500 crore (USD 0.3 million) to develop novel vaccines and gene therapies in the new facility in Nashik. The company plans to produce complicated monoclonal antibodies, plasma proteins, and biosimilar products to treat patients in critical care.
Also, an increase in the geriatric population in India is another reason for the market growth during the forecast period. Also, the most common causes of hypoalbuminemia include liver disease, heart failure, malnutrition, or vitamin deficiency. Malnutrition is a highly prevalent condition among the geriatric population, and proper nutritional intake is required to be healthy. According to the India Ageing Report 2023, India's aging population is increasing at a moderate pace. Projections showed that the proportion of elderly individuals in South Asia will reach 20% by 2022 and 36.1% by 2050. The geriatric population in India is expected to utilize plasma products, driving market growth during the forecast period.
Thus, owing to the increase in investment and government initiatives to support plasma fractionation and the rise in strategic activities by the key players, the market is expected to witness notable growth in India during the forecast period. However, the high cost of blood plasma products is expected to hinder market growth during the forecast period.
India Plasma Fractionation Market Trends
The Platelets and Coagulation Factor Concentrates Segment is Expected to Witness a Positive Growth Over the Forecast Period
Platelets and coagulation factors commonly treat bleeding episodes and prevent surgical bleeding in patients with von Willebrand disease, congenital bleeding disorder, Hemophilia B, and many more diseases. Platelets participate in hemostasis, or they form clots to stop bleeding. Factors such as increased injury cases, a rise in surgical procedures, and a high prevalence of thrombocytopenia among the Indian population are expected to drive market growth during the forecast period. For instance, according to the Road Accident Statistics in India 2022 report, Police Departments across States and Union Territories (UTs) reported 461,312 road accidents in the country in 2022. These accidents resulted in 168,491 fatalities and injured 443,366 individuals in India. Due to India's high number of injury cases, the demand for platelets and coagulation factors is expected to rise, contributing to the segment growth during the forecast period.
Also, an increase in blood donation campaigns and blood distribution efforts by government authorities is expected to fuel the segment growth during the forecast period. For instance, 51,726 blood/blood components were prepared by the Indian Red Cross during 2022-2023. A total of 17,052 units of blood components were issued free of cost to the thalassaemic and hemophilic patients, as well as those admitted to government hospitals. Also, 13,210 units of blood were issued against processing charges to the patients admitted to private hospitals/nursing homes. Since the donated blood contains plasma, red and white blood cells, platelets, antibodies, and other components, such initiatives are expected to increase the fractionation of plasma products and promote segment growth during the forecast period.
Thus, owing to the rise in injury cases that require blood transfusion and the increase in blood donation campaigns in India, the segment is expected to witness significant growth during the forecast period.
The Hematology Segment is Expected to Witness Healthy Growth in the Market During the Forecast Period
The hematology segment is expected to experience significant growth in the market due to the rising prevalence of hematological diseases such as anemia, bleeding disorders like hemophilia, blood clots, and blood cancers such as leukemia, lymphoma, and myeloma. This growth is attributed to increased government initiatives to educate the Indian population about seeking treatment. For instance, according to the 7th Mission Steering Group meeting conducted by the National Health Mission (NHM), 0.1 million people were screened for sickle cell disease in India in 2023. Of those screened, 5,959 people, or 5.62%, were found to carry sickle cell disease traits in India. Similarly, according to the article published in October 2022 in the Journal of Community Genetics, SCD prevalence was high among Indian indigenous tribal communities. Thus, owing to the presence of sickle cell disease (SCD) among the Indian population, the demand for plasma fractionation is expected to rise, leading to market growth during the forecast period.
Also, the increase in financial support and funding offered by the government authorities for the treatment of hematological diseases in India is expected to drive market growth during the forecast period. For instance, during the 2023 India budget, the National Health Mission (NHM) proposed INR 542 crore (USD 65.46 million) to diagnose, treat, and eliminate sickle cell anemia by 2047 in India. Thus, such investments in India are expected to urge the development of various plasma products and lead to the growth of plasma fractionation products in India.
Hence, due to the increase in various hematological diseases and the rise in financial support by government agencies to aid in the treatment of hematological diseases, the segment is expected to witness significant growth during the forecast period.
India Plasma Fractionation Industry Overview
The Indian plasma fractionation market is fragmented due to the presence of many companies operating globally and regionally. Key companies are strategically involved in many activities, such as product launches, partnerships, and acquisitions, to increase their presence around the globe. A few major companies in the market are Virchow Biotech Private Limited, Taj Pharmaceuticals Limited, Intas Pharmaceuticals Ltd, Reliance Industries Limited (Reliance Life Sciences), and PlasmaGen BioSciences Pvt. Ltd.
India Plasma Fractionation Market Leaders
-
PlasmaGen BioSciences Pvt. Ltd.
-
Reliance Industries Limited (Reliance Life Sciences)
-
Intas Pharmaceuticals Ltd
-
Taj Pharmaceuticals Limited
-
Virchow Biotech Private Limited
- *Disclaimer: Major Players sorted in no particular order
India Plasma Fractionation Market News
- June 2024: Plasmagen Biosciences, based in Bengaluru and focused solely on plasma protein and specialty care therapy, unveiled the launch of Haemocomplettan P (human fibrinogen concentrate). This product is produced by CSL Behring, a division of the globally recognized biotechnology company CSL. Haemocomplettan P is set to support 150,000 cardiac surgeries and more than 1,800 liver transplant procedures.
- May 2023: PlasmaGen Biosciences, a biopharmaceutical company focused on blood plasma-derived pharmaceutical products for India and emerging markets, inaugurated its new manufacturing plant for blood plasma-derived protein therapeutics in Kolar, Bengaluru.
India Plasma Fractionation Industry Segmentation
As per the scope of the report, plasma fractionation is defined as the general process of separating the various components of blood plasma obtained via blood fractionation. Plasma contains multiple proteins, including immunoglobulins, albumin, and coagulation proteins.
The Indian plasma fractionation market is segmented by product, application, and end user. By product, the market is segmented into immunoglobulins, platelets and coagulation factor concentrates, albumin, and other products. By application, the market is segmented into neurology, immunology, hematology, and other applications. By end user, the market is segmented into hospitals and clinics, clinical research laboratories, and other end users. The other end users include academia and research institutes. The report offers market size and forecasts in value (USD) for the above segments.
| By Product | Immunoglobulins |
| Platelets and Coagulation Factor Concentrates | |
| Albumin | |
| Other Products | |
| By Application | Neurology |
| Immunology | |
| Hematology | |
| Other Applications | |
| By End User | Hospitals and Clinics |
| Clinical Research Laboratories | |
| Other End Users |
| Immunoglobulins |
| Platelets and Coagulation Factor Concentrates |
| Albumin |
| Other Products |
| Neurology |
| Immunology |
| Hematology |
| Other Applications |
| Hospitals and Clinics |
| Clinical Research Laboratories |
| Other End Users |
India Plasma Fractionation Market Research Faqs
How big is the India Plasma Fractionation Market?
The India Plasma Fractionation Market size is expected to reach USD 1.77 billion in 2025 and grow at a CAGR of 6.39% to reach USD 2.41 billion by 2030.
What is the current India Plasma Fractionation Market size?
In 2025, the India Plasma Fractionation Market size is expected to reach USD 1.77 billion.
Who are the key players in India Plasma Fractionation Market?
PlasmaGen BioSciences Pvt. Ltd., Reliance Industries Limited (Reliance Life Sciences), Intas Pharmaceuticals Ltd, Taj Pharmaceuticals Limited and Virchow Biotech Private Limited are the major companies operating in the India Plasma Fractionation Market.
What years does this India Plasma Fractionation Market cover, and what was the market size in 2024?
In 2024, the India Plasma Fractionation Market size was estimated at USD 1.66 billion. The report covers the India Plasma Fractionation Market historical market size for years: 2019, 2020, 2021, 2022, 2023 and 2024. The report also forecasts the India Plasma Fractionation Market size for years: 2025, 2026, 2027, 2028, 2029 and 2030.
India Plasma Fractionation Industry Report
Statistics for the 2025 India Plasma Fractionation market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. India Plasma Fractionation analysis includes a market forecast outlook for 2025 to 2030 and historical overview. Get a sample of this industry analysis as a free report PDF download.
